SCHEMBL25218344

SCHEMBL25218344

O=[N+]([O-])c1ccc(-n2cccn2)cc1Br

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP19A1 P11511 2/20 0.43
NOTUM Q6P988 1/20 0.42
MAPT P10636 8/20 0.40
MEN1 O00255 8/20 0.40
KMT2A Q03164 8/20 0.40
LMNA P02545 5/20 0.40
HTT P42858 1/20 0.40
MDM2 Q00987 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
AAK1 Q2M2I8 1/20 0.39
DCTPP1 Q9H773 1/20 0.39
RAB9A P51151 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31277054 1.00 ALDH1A1 (0.43) ALDH1A1KDM4EMAPK1CYP19A1NOTUM
SCHEMBL4137682 0.82 HPGD (0.51) ALDH1A1KDM4EMAPK1NOTUMMAPT
SCHEMBL5333636 0.82 LMNA (0.52) ALDH1A1KDM4EMAPK1NOTUMMAPT
SCHEMBL19260129 0.82 MAPT (0.49) ALDH1A1KDM4EMAPK1NOTUMMAPT
SCHEMBL16150794 0.79 ALDH1A1 (0.47) ALDH1A1KDM4EMAPK1NOTUMMAPT
SCHEMBL27853895 0.79 MAPT (0.48) ALDH1A1KDM4EMAPK1NOTUMMAPT
SCHEMBL31129883 0.79 NOTUM (0.46) CYP19A1NOTUMAAK1
SCHEMBL8302020 0.79 DTYMK (0.48) ALDH1A1KDM4EMAPK1CYP19A1NOTUM
SCHEMBL8427201 0.79 GRIA1 (0.40) ALDH1A1KDM4EMAPK1NOTUMMAPT
SCHEMBL13206126 0.76 ALDH1A1 (0.42) ALDH1A1KDM4EMAPK1NOTUMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197375-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. 2025-06-19 US disclosed
WO-2025059577-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS ATAVISTIK BIO, INC. (US) 2025-03-20 WO disclosed
EP-4444309-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 EP disclosed
WO-2023107603-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197375-A1 PYRIMIDINES AND METHODS OF THEIR USE TDP1, TYMP, TARDBP ALDH1A1 2220/4885KDM4E 3020/4885MAPK1 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.